Biocytogen Secures USD 142M in series D1 Round of Financing

In August, Beijing Biocytogen Biotechnology announced the acquisition of Eucure Biopharma, which established Biocytogen as a clinical-stage company.

FREMONT, CA: Biocytogen, a Chinese clinical-stage company, raised $142 million in its series D1 funding. The round was led by CMB International, with participation from investor partners PICC Capital, SDIC Ventures, China Life Equity, 3E Bioventures, Cowin Capital, and Baifu Capital.

Led by Chairman and CEO Dr.YueleiShen, Biocytogen is a global biotech company that drives the research and development of new drugs with innovative technologies. The company works jointly with international partners to accelerate new drug discovery and development.

The company intends to use the funds to further secure the implementation of Project Integrum, a humanitarian effort to discover, develop, and bring to market novel therapeutic antibody candidates against all notoriously difficult druggable targets. Taking full advantage of Biocytogen’s integrated technology platforms for antibody discovery, Project Integrum will launch pre-clinical efforts into over 1,000 human diseases currently affecting countless lives.

Whether it’s with RenMab-based target knockout mice, customized target humanized mouse models, in vivo pharmacology screening platforms, or even companion dog translational medicine, Biocytogen is determined to find antibodies with clinical translative value.